دانلود مقالات ISI درباره منطقه پسوریازیس و شاخص شدت + ترجمه فارسی
Psoriasis Area And Severity Index
منطقه پسوریازیس و شاخص شدت
در این صفحه تعداد 97 مقاله تخصصی درباره منطقه پسوریازیس و شاخص شدت که در نشریه های معتبر علمی و پایگاه ساینس دایرکت (Science Direct) منتشر شده، نمایش داده شده است. برخی از این مقالات، پیش تر به زبان فارسی ترجمه شده اند که با مراجعه به هر یک از آنها، می توانید متن کامل مقاله انگلیسی همراه با ترجمه فارسی آن را دریافت فرمایید. در صورتی که مقاله مورد نظر شما هنوز به فارسی ترجمه نشده باشد، مترجمان با تجربه ما آمادگی دارند آن را در اسرع وقت برای شما ترجمه نمایند.
مقالات ISI منطقه پسوریازیس و شاخص شدت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند. در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: منطقه پسوریازیس و شاخص شدت; dose escalation; dose optimization; psoriasis; secukinumab; AE; adverse event; PASI; Psoriasis Area and Severity Index; PASI-75; 75% reduction from baseline PASI score; PGA; Physician Global Assessment;
Keywords: منطقه پسوریازیس و شاخص شدت; ISS; itch severity scale; NRS; numeric rating scale; PASI; Psoriasis Area and Severity Index; QoL; quality of life; VAS; visual analog scale;
Keywords: منطقه پسوریازیس و شاخص شدت; discontinuation; methotrexate; moderate-to-severe psoriasis; Psoriasis Area and Severity Index (PASI); prediction; response; AUC; area under the curve; DLQI; Dermatology Life Quality Index; ITT; intent-to-treat; PASI; Psoriasis Area and Severity Index; PA
Keywords: منطقه پسوریازیس و شاخص شدت; ACR; American College of Rheumatology; bDMARDs; biologic disease-modifying antirheumatic drugs; DMARDs; disease-modifying antirheumatic drugs; EULAR; European League Against Rheumatism; GRAPPA; Group for Research and Assessment of Psoriasis and Psoriatic
Keywords: منطقه پسوریازیس و شاخص شدت; AUC; area under the receiver operating characteristic curve; PASI; Psoriasis Area and Severity Index; PASI75; at least 75% reduction in Psoriasis Area and Severity Index score; UPSC; universal psoriasis skin classifier;
Keywords: منطقه پسوریازیس و شاخص شدت; CI; confidence interval; DLQI; dermatology life quality index; NMA; network meta-analysis; PASI; psoriasis area and severity index; RCT; randomized controlled trial; SUCRA; surface under the cumulative ranking curve;
Keywords: منطقه پسوریازیس و شاخص شدت; biological therapy; psoriasis; ustekinumab; ADA; antidrug antibodies; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index;
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; cost per responder; cost-effectiveness; indirect comparison; methotrexate; moderate to severe psoriasis; number needed to treat; Psoriasis Area and Severity Index; AAD; American Academy of Dermatology; CI; confidence interval; FDA; Food and Dr
Keywords: منطقه پسوریازیس و شاخص شدت; health state utility; psoriasis; Psoriasis Area and Severity Index; quality of life; time trade-off; willingness to pay;
Keywords: منطقه پسوریازیس و شاخص شدت; etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
Keywords: منطقه پسوریازیس و شاخص شدت; Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Keywords: منطقه پسوریازیس و شاخص شدت; Dermatology Life Quality Index; patient-reported outcome; Physician Global Assessment; psoriasis; Psoriasis Area and Severity Index; quality of life; BSA; body surface area; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-rela
Keywords: منطقه پسوریازیس و شاخص شدت; Psoriasis; Comorbilidades; Criterios de gravedad: BSA; Body Surface Area; PASI; Psoriasis Area and Severity Index; DLQI; Dermatology Life Quality Index; Fototerapia; Retinoides; Metotrexato; Ciclosporina; Terapia biológica;
Keywords: منطقه پسوریازیس و شاخص شدت; Beau lines; epidemiology; leukonychia; nail psoriasis; Nail Psoriasis Severity Index; nails; onycholysis; psoriasis; splinter hemorrhages; NAPSI; Nail Psoriasis Severity Index; PASI; Psoriasis Area and Severity Index; PsA; psoriatic arthritis;
Keywords: منطقه پسوریازیس و شاخص شدت; ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
Keywords: منطقه پسوریازیس و شاخص شدت; AE; adverse event; BADBIR; British Association of Dermatologists Biologic Interventions Register; CI; confidence interval; HR; hazard ratio; PASI; Psoriasis Area and Severity Index; TNFI; tumor necrosis factor inhibitors;
Keywords: منطقه پسوریازیس و شاخص شدت; atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
Keywords: منطقه پسوریازیس و شاخص شدت; cumulative benefit; itching; pain; psoriasis; quality of life; scaling; secukinumab; AUC; area under the curve; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-related quality of life; MCID; minimal clinically important differ
Keywords: منطقه پسوریازیس و شاخص شدت; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; â¥50% reduction in PASI from
Keywords: منطقه پسوریازیس و شاخص شدت; ApoE; apolipoprotein E; IMQ; imiquimod; TC; total cholesterol; TG; triglycerides; LDL; low density lipoproteins; HDL; high density lipoproteins; PASI; psoriasis area and severity index; PPARs; peroxisome proliferator activated receptors; IL; interleukin;
Keywords: منطقه پسوریازیس و شاخص شدت; ABP 501; adalimumab; biosimilar; efficacy; equivalence; psoriasis; safety; ADA; antidrug antibody; CI; confidence interval; PASI; Psoriasis Area and Severity Index; PASI 50; 50% or more improvement in Psoriasis Area and Severity Index score from baseline;
Keywords: منطقه پسوریازیس و شاخص شدت; PBMC; peripheral blood mononuclear cells; TCM; central memory T cells; TEM; effector memory T cells; TEFF; effector T cells; PASI; Psoriasis Area and Severity Index; CRP; C-reactive protein; CLA; cutaneous lymphocyte-associated antigen; Th1; T helper 1 ce
Keywords: منطقه پسوریازیس و شاخص شدت; psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Keywords: منطقه پسوریازیس و شاخص شدت; aTreg; activated regulatory T cells; Foxp3; forkhead-box p3; IL; interleukin; non-Treg; non-suppressive regulatory T cells; PASI; Psoriasis Area and Severity Index; PUVA; psoralen plus ultraviolet light A; rTreg; resting regulatory T cells; Th17; interleu
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; difficult to treat; ESTEEM; moderate to severe; palmoplantar psoriasis; palms; PSOR-005; soles; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; IL; interleukin; m-PPPASI; modified Palmoplantar Psoriasis Are
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;
Keywords: منطقه پسوریازیس و شاخص شدت; adalimumab; etanercept; failure; infliximab; psoriasis; switching; tumor necrosis factor antagonist; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index; PASI50; 50% improvement in Psoriasis Area and Severity Index score; PASI75;
Keywords: منطقه پسوریازیس و شاخص شدت; CTLA4; cytotoxic T-lymphocyte-associated protein 4; DEG; differentially expressed gene; FDR; false discovery rate; GSVA; gene set variation analysis; K16; keratin 16; PASI; Psoriasis Area and Severity Index; TH; T helper; Treg; regulator T cell;
Keywords: منطقه پسوریازیس و شاخص شدت; CTLA4; cytotoxic T lymphocyte-associated protein 4; FoxP3; forkhead box P3; PASI; psoriasis area and severity index; TNF; tumor necrosis factor; Treg; regulatory T cell;
Keywords: منطقه پسوریازیس و شاخص شدت; HLA; human leukocyte antigen; HLA-C*06:02-POS; HLA-C*06:02-positive; HLA-C*06:02-NEG; HLA-C*06:02-negative; PASI; Psoriasis Area and Severity Index; PASI 50/75/70; 50/75/90% improvement from baseline in Psoriasis Area and Severity Index; TNF; tumor necros